{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:55:18Z","timestamp":1788188118813,"version":"build-2803163510"},"reference-count":0,"publisher":"Georg Thieme Verlag KG","issue":"01","license":[{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Introduction\u2003This X-VeRT (eXplore the efficacy and safety of once-daily oral riVaroxaban for the prevention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion) substudy evaluated the effects of treatment with rivaroxaban or a vitamin-K antagonist (VKA) on levels of biomarkers of coagulation (D-dimer, thrombin\u2013antithrombin III complex [TAT] and prothrombin fragment [F1.2]) and inflammation (high sensitivity C-reactive protein [hs-CRP] and high-sensitivity interleukin-6 [hs-IL-6]) in patients with atrial fibrillation (AF) who were scheduled for cardioversion and had not received adequate anticoagulation at baseline (defined as, in the 21 days before randomization: no oral anticoagulant; international normalized ratio &lt;2.0 with VKA treatment; or &lt;80% compliance with non-VKA oral anticoagulant treatment).<\/jats:p><jats:p>\n          Methods\u2003Samples for biomarker analysis were taken at baseline (n\u2009=\u2009958) and treatment completion (42 days after cardioversion; n\u2009=\u2009918). The influence of clinical characteristics on baseline biomarker levels and the effect of treatment on changes in biomarker levels were evaluated using linear and logistic models.<\/jats:p><jats:p>\n          Results\u2003Baseline levels of some biomarkers were significantly associated with type of AF (D-dimer and hs-IL-6) and with history of congestive heart failure (hs-CRP, D-dimer, and hs-IL-6). Rivaroxaban and VKA treatments were associated with reductions from baseline in levels of D-dimer (\u221232.3 and \u221237.6%, respectively), TAT (\u221228.0 and \u221223.1%, respectively), hs-CRP (\u221212.5 and \u221217.9%, respectively), and hs-IL-6 (\u22129.2 and \u22129.8%, respectively). F1.2 levels were reduced from baseline in patients receiving a VKA (\u221253.0%) but not in those receiving rivaroxaban (2.7%).<\/jats:p><jats:p>\n          Conclusion\u2003Anticoagulation with rivaroxaban reduced levels of key inflammation and coagulation biomarkers to a similar extent as VKAs, with the exception of F1.2. Further investigation to confirm the value of these biomarkers in patients with AF is merited.<\/jats:p>","DOI":"10.1055\/s-0040-1701206","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T20:28:03Z","timestamp":1579811283000},"page":"e20-e32","source":"Crossref","is-referenced-by-count":44,"title":["Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial"],"prefix":"10.1055","volume":"04","author":[{"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Sciences, University of Birmingham, Sandwell and West Birmingham Hospitals NHS Trust and University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom"},{"name":"Department of Cardiology, University Heart Center Hamburg, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Ezekowitz","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Sidney Kimmel Medical College, Thomas Jefferson University, and the Lankenau Medical Center, Philadelphia, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanish","family":"Purmah","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Sciences, University of Birmingham, Sandwell and West Birmingham Hospitals NHS Trust and University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Schiffer","sequence":"additional","affiliation":[{"name":"Translational Medicine, Global R&D, Bayer AG, Wuppertal, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle L.","family":"Meng","sequence":"additional","affiliation":[{"name":"Therapeutic Area Cardiovascular, Global Medical Affairs, Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. John","family":"Camm","sequence":"additional","affiliation":[{"name":"Division of Clinical Sciences, St George's, University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan H.","family":"Hohnloser","sequence":"additional","affiliation":[{"name":"Division of Clinical Electrophysiology, Department of Cardiology, J. W. Goethe University, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Schulz","sequence":"additional","affiliation":[{"name":"Clinical Statistics EU, Global Clinical Development, Research and Clinical Sciences Statistics, Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Wosnitza","sequence":"additional","affiliation":[{"name":"Therapeutic Area Cardiovascular, Global Medical Affairs, Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Cappato","sequence":"additional","affiliation":[{"name":"Arrhythmia and Electrophysiology Research Center, Humanitas Clinical and Research Center, Rozzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,1,23]]},"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1701206.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T19:24:13Z","timestamp":1580930653000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1701206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":0,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2020,1,7]]},"published-print":{"date-parts":[[2020,1]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1701206","relation":{},"ISSN":["2512-9465"],"issn-type":[{"value":"2512-9465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}